Neuro-Oncology
NF2-related schwannomatosis
Dec. 13, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Glioblastoma, IDH wildtype …
- Updated 01.03.2024
- Released 01.16.2020
- Expires For CME 01.03.2027
Glioblastoma, IDH wildtype
Introduction
Overview
Glioblastoma is the most common primary malignant brain tumor in the adult population. The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System revised adult-type diffuse gliomas into three distinct tumor types: (1) glioblastoma, isocitrate dehydrogenase (IDH) wildtype, CNS WHO grade 4; (2) astrocytoma, IDH-mutant, CNS WHO grade 2-4; (3) oligodendroglioma, IDH-mutant, 1p/19q-codeleted, CNS WHO grade 2-3. This article focuses specifically on the diagnosis and management of glioblastoma, IDH wildtype, CNS WHO grade 4.
Key points
|
• Glioblastoma, IDH wildtype, is the most common malignant primary brain tumor with an often-aggressive clinical course. | |
|
• Treatment of glioblastoma, IDH wildtype, is multimodal and includes maximal safe surgical resection, fractionated radiation, chemotherapy, and tumor-treating fields. | |
|
• Age and performance status at diagnosis in glioblastoma IDH wildtype may influence optimal dosing of radiation and chemotherapy. | |
|
• Molecular testing should be considered in glial neoplasms that are IDH1 R132H wildtype by immunohistochemistry with high clinical or radiologic suspicion for other high-grade gliomas, including non-canonical IDH-mutated high-grade gliomas, diffuse midline gliomas with H3 K27-altered, and diffuse hemispheric gliomas with H3 G34 mutated; potential targetable mutations should be evaluated. | |
|
• Astrocytomas, IDH mutant WHO grade 4; diffuse midline gliomas with H3 K27-altered; diffuse hemispheric gliomas with H3 G34 mutation; pleomorphic xanthoastrocytomas; and other distinct entities are defined by other features and are not discussed in detail in this review. |
Clinical manifestations
Presentation and course
Glioblastoma, IDH wildtype, is an aggressive tumor with a median age at diagnosis of 68 to 70 years (41). Presenting symptoms vary depending on tumor location and may also present with signs of increased intracranial pressure. Glioblastoma, IDH wildtype, are less likely to present with seizures (18% to 34%) when compared to IDH mutant tumors (59% to 74%), which may be related to the excitatory potential of D-2-hydroxygluterate, the metabolic product of the mutated IDH enzyme gene (11). Glioblastoma IDH wildtype are more likely to present with cognitive impairment in memory and processing speed as well as visuospatial, language, and executive function hypothesized to be secondary to rate of growth (55).
Prognosis and complications
Prognosis for glioblastoma, IDH wildtype, is poor with median survival of 15 to 21 months. Known key prognostic factors include age at diagnosis, functional status, extent of resection, and MGMT promoter methylation status (52; 48; 36). These are discussed in further detail below.
Clinical vignette
Vignette 1. A 53-year-old right-handed male with history of well controlled hypertension and diabetes presented with 2 weeks dizziness, headaches, and falls. His examination was notable for mild left facial weakness, and MRI revealed a large right temporal enhancing mass with midline shift and herniation. He underwent gross total resection of the right temporal mass with pathology consistent with glioblastoma, IDH wildtype, CNS WHO grade 4, and MGMT promoter methylated. Postoperatively, he had mild left-sided weakness and went on to receive fractionated radiation with concurrent temozolomide followed by six cycles of adjuvant temozolomide. He continued stable and free of disease progression at examination 27 months after diagnosis.
Vignette 2. A 68-year-old right-handed male with history of hypertension presented with a week of right focal motor seizure without loss of consciousness. MRI revealed a minimally enhancing, infiltrative mass in the left cingulate. After his seizures were controlled, he underwent gross total resection of the left cingulate mass with histopathology assessment consistent with high-grade astrocytoma without presence of microvascular proliferation or necrosis. However, given his age and the lack of IDH mutation on immunohistochemistry, subsequent sequencing identified amplification of EGFR, which is one of the hallmark molecular features of glioblastoma, IDH wildtype, CNS WHO grade 4. He went on to receive radiation and concurrent temozolomide.
These two clinical vignettes highlight the heterogeneity of neurologic symptoms and radiologic findings of glioblastoma and importance of thorough pathologic review, including sequencing in cases with high clinical suspicion of glioblastoma.
Biological basis
Etiology and pathogenesis
|
• Neural stem cells or glial precursor cells are hypothesized to be the origin of glioblastoma. | |
|
• Most often, no identifiable risk factors can be found. Known risk factors include ionizing radiation (primarily in childhood) and rare hereditary mutations, including, but not limited to, Li-Fraumeni (germline mutation in TP53) or other germline mutations, especially mutations in DNA mismatch repair genes. |
Stem-like cells within the CNS are hypothesized to be cells of origin of glioblastoma, IDH wildtype (01). Several genetic risk factors for gliomas are now known, including rare mutations confined to specific families and more common inherited variants in independent genetic loci (45; 23; 35). Known single gene disorders include, but are not limited to, Lynch and Li-Fraumeni syndromes as well as neurofibromatosis and tuberous sclerosis, which all predispose to glioma formations (23).
Exposure to ionizing radiation, particularly in childhood, remains the strongest environmental risk factor for diffuse glioma (07).
Glioblastoma, IDH wildtype, is a heterogeneous tumor at the cellular level with multiple alterations in numerous pathways. Commonly altered genes and molecular profiles include amplification of EGFR, TERT promotor mutation, and gain of chromosome 7 and loss of chromosome 10 (loss of PTEN) (54).
Data from The Cancer Genome Atlas (TCGA) identified numerous mutations within key pathways of (1) receptor kinases (EGFR, PDGFRA), RAS (NF1), and PI3K (PTEN) dysregulating cell proliferation; (2) p53 signaling pathway (CDKN2A, MDM2/4) activation of the oncogene; and (3) RB signaling pathway (CDK4, CDKN2A/B, RB) resulting in inappropriate progression through the cell cycle (09).
Additional molecular testing for BRAF V600E mutations and NTRK fusions should be considered given potential clinical trial and therapeutic clinical implications (14; 57). Epithelioid glioblastomas (a histologic description not codified in the current WHO classification system) show a high percentage of BRAF V600 mutations (27; 34).
For a more detailed glioblastoma IDH wildtype neuropathology review, please see Overview of neuropathology updates for infiltrating gliomas.
Epidemiology
Glioblastoma accounts for 49.1% of malignant non-metastatic brain tumors and 15% of all CNS tumors in adults (41; 31). The incidence of glioblastoma, IDH wildtype, increases with age and peaks between 75 and 84 years of age, with a median age at diagnosis of 68 to 70 years (41). There is a higher incidence in men than in women and in non-Hispanic white compared to Hispanic white and black individuals (41).
Although the incidence of glioblastoma is low compared to several other malignancies, glioblastoma is associated with considerable morbidity and mortality.
Differential diagnosis
Confusing conditions
|
• Other gliomas, including astrocytoma, IDH mutated; oligodendrogliomas; pleomorphic xanthoastrocytomas (PXA); diffuse midline gliomas with H3 K27-altered; and diffuse hemispheric gliomas with H3 G34 mutation | |
|
• Metastases | |
|
• CNS lymphoma | |
|
• Infectious etiologies | |
|
• Autoimmune etiologies, including tumefactive multiple sclerosis as well as sarcoidosis | |
|
• Subacute stroke (which may enhance on post-contrast imaging) |
Diagnostic workup
|
• Per the 2021 WHO classification of CNS tumors, the following criteria have to be met for a diagnosis of glioblastoma: IDH wildtype, H3 wildtype, diffuse astrocytic neoplasm, morphologic features of microvascular proliferation or necrosis, or at least one of the following molecular alterations—EGFR amplification, TERT promotor mutation, and gain of chromosome 7 and loss of chromosome 10 (Chr +7/-10). | |
|
• Molecular testing is frequently obtained to better identify the tumor subtype as well as to assess for potential targetable mutations, including BRAF V600 and NTRK fusions. |
Contrast-enhanced MRI is the standard for identification of mass lesion in the brain. The majority of glioblastomas, IDH wildtype, are T2-weighed hyperintense and T1-weighed hypointense lesions with heterogenous contrast enhancement often associated with significant edema secondary to their high vascularity and disruption of the blood-brain barrier (39; 46). However, contrast-enhancement is not an absolute surrogate for tumor histology, with some glioblastoma lacking contrast enhancement and several low-grade gliomas avidly contrast-enhancing (46). Glioblastomas may be a single radiographic lesion, multicentric, or multifocal, and particular attention should be given to evaluate for additional, distant areas of T2/FLAIR hyperintensity that may not enhance but may be additional sites of disease, especially if these lesions appear expansile (03). Depending on patient history, radiologic differential diagnosis, etc., CT of chest, abdomen, and pelvis could be considered for evaluation of systemic cancer (02). In routine practice this is often unnecessary.
Histopathologic criteria for glioblastoma include the presence of microvascular proliferation and necrosis (29). WHO revised the classification of CNS tumors in 2016, and again in 2021, to incorporate molecular markers into histopathology for an integrated diagnosis (30; 08). Assessment of IDH status is imperative for an accurate classification of the tumor. An immunohistochemical stain for IDH 1 (R132H) mutant protein, which accounts for approximately 85% of IDH mutations in adult-type diffuse gliomas, is available for clinical use. If a non-canonical IDH mutation is suspected, next-generation sequencing should be performed to screen for the absence of an IDH mutation.
Molecular testing should be considered to assess for potential targetable mutations and to evaluate for the hallmark molecular alterations (EGFR amplification, the combined gain of chromosome 7 and loss of chromosome 10, or TERT promoter mutation) that are consistent with a diagnosis of glioblastoma, IDH wildtype, CNS WHO grade 4, and share a survival experience similar to glioblastoma (08). This is often done by a broad next-generation sequencing panel. DNA methylation signatures are also increasingly being used to subclassify brain tumors, with fewer technical limitations (10; 22). There is often greater value in extensive next generation sequencing than in the performance of numerous immunohistochemical stains, which utilize tissue and do not help refine the diagnosis nor guide management.
Though not incorporated into the revised WHO 2021 brain tumor classification system, the DNA repair enzyme 6-0-methylguanine-DNA methyltransferase (MGMT) is an important prognostic and predictive biomarker in glioblastoma, IDH wildtype. Functionally, MGMT allows repair of DNA damage caused by alkylating chemotherapy, such as temozolomide discussed in detail below (19). However, sensitivity to temozolomide is increased when MGMT is silenced via promoter methylation (59). MGMT is methylated in approximately 40% of glioblastoma, IDH wildtype, and is not only a predictor of response to temozolomide but is also a prognostic marker (05; 06; 21) and is particularly helpful in treatment decisions in the elderly as discussed below.
Management
Surgery. Maximum resection of area of contrast enhancement is associated with prolonged survival in glioblastoma (33; 44; 47). Postoperative residual enhancement is also inversely associated with improved outcomes in glioblastoma (16). For tumors in eloquent areas, use of intraoperative stimulation mapping significantly decreases risk of severe delayed neurologic deficits and have both been shown to increase extent of resection for glioblastoma (15).
Consideration should be given for referral to high volume center given complexity of treatment, particularly resection, and opportunities for clinical trial (including surgically based trial) participation.
Radiation and chemotherapy. Due to the infiltrative nature of glioblastoma, maximum resection is not considered curative. Since 2005, fractionated radiation to 60 Gy in approximately 30 fractions with concurrent and adjuvant temozolomide has been the standard of care (49; 50). Adding the alkylating agent, temozolomide, to fractionated radiation improved overall survival by almost 3 months. Temozolomide is given concomitant with radiation at 75 mg/m2 followed by adjuvant treatment at 150 to 200 mg/m2 on days 1 to 5 of a 28-day cycle, typically for six cycles. Data from the GEINO trial of randomizing patients to either 6 or 12 months of adjuvant temozolomide demonstrated no significant differences 6-month progression-free survival, progression-free survival, or overall survival, demonstrating there is no significant benefit in unselected populations for 12 months of adjuvant temozolomide (04). The limited number of patients in this trial makes it underpowered to detect subtle differences in outcomes between the two arms.
In the CeTeG/NOA-09 trial, temozolomide was combined with another alkylating agent, lomustine (CCNU), in the upfront setting in patients with MGMT methylated glioblastoma. Results from the relatively small phase 3 study demonstrated survival improvement; marked toxicity was also seen (24; 54) (56). Additional investigation in a larger trial, NCT05095376, is currently ongoing.
The published results from the DCVax®-L trial (NCT00045968) showed improved overall survival in the vaccine group when compared to a composite historical control (28). However, it did not demonstrate an improvement in survival in the investigational arm compared to the control arm.
Use of anti-angiogenic agents, such as bevacizumab, in unselected, newly diagnosed glioblastoma has shown no improvement in overall survival in two phase 3 trials (12; 20). Additionally, randomized controlled, double blinded trials of checkpoint inhibition with nivolumab in combination with radiation and temozolomide in either MGMT methylated or unmethylated in newly diagnosed glioblastoma failed to demonstrate improvement in overall survival above standard of care (40). Though immunotherapy is being heavily investigated in clinical trials, there is, as yet, no evidence for efficacy in unselected patients with glioblastoma.
Tumor-treating fields. Tumor-treating fields were first approved in 2011 in the recurrent setting of glioblastoma (53) and then approved in 2015 for use in newly diagnosed glioblastoma in conjunction with adjuvant temozolomide after completion of radiation and concurrent chemotherapy (50; 51). Results from the phase 3 EF-14 study demonstrated an improvement in overall survival of nearly 5 months with the addition of tumor-treating fields to temozolomide; they are now incorporated into the NCCN guidelines (37). Tumor-treating fields consist of a set of arrays, directly applied to the scalp, which deliver two relatively perpendicular alternating electrical fields of low voltage and moderate frequency, tuned to a frequency to disrupt mitotic activity of glioblastoma cells (25; 26; 18).
Palliative care. Glioblastoma, IDH wildtype, is a terminal illness and falls under the guidelines from the NCCN (38) and ASCO (American Society of Clinical Oncology) (17) for early intervention with palliative care.
Recurrent disease. There is no standard of care for treatment at recurrence. Whenever feasible, consideration should be given to enrollment in a clinical trial. FDA-approved treatments are limited and include bevacizumab with or without concurrent cytotoxic chemotherapy, such as lomustine. However, additional resection, re-irradiation, re-challenge with temozolomide, targeted agents, and immunotherapy may be considered in the correct clinical scenario.
Prophylaxis. Pneumocystis pneumonia prophylaxis with trimethoprim-sulfamethoxazole during temozolomide treatment should be considered in patients with other risk factors for opportunistic infections (long-term steroid use and significant lymphopenia), but in otherwise immunologically healthy patients, the risk may outweigh the benefits (13).
Outcomes
Median overall survival continues to be around 15 to 21 months (51; 36), and less than 10% to 15% of patients survive 5 years after diagnosis (48; 51). Prognostic factors include age and performance status at diagnosis, extent of resection, and MGMT promoter methylation status.
Nomograms have been created to help estimate prognosis based on specific patient characteristics. One of these nomograms can be found via this link: npatilshinyappcalculator.shinyapps.io/SexDifferencesInGBM/(42).
Special considerations
Many glioblastoma, IDH wildtype, patients are diagnosed in their 70s and 80s (36). However, many clinical trials that defined the standard of care for these patients excluded patients older than 70 years of age, leaving a gap in optimal treatment for this large subset of patients (52). Given the toxicities of fully fractionated radiation and the overall worse outcomes in elderly patients, several trials investigated alternate dosing of radiation and chemotherapy (32; 58; 43). Hypofractionated radiation to 40 Gy in 15 fractions and temozolomide should be considered in patients older than 65 years at diagnosis (43; 60). Furthermore, treatment with only radiotherapy should be considered in elderly patients or those with poor functional status with MGMT unmethylated tumors (32; 58). Although these approaches are largely pragmatic, there may be biological underpinnings requiring further exploration as to why they may be beneficial (24).
Pregnancy
Temozolomide is mutagenic and is contraindicated during pregnancy. Extensive caution is taken when considering the role of radiation therapy in pregnancy. Breastfeeding is also contraindicated with temozolomide therapy. It is unknown what the effects of tumor-treating fields may be in the setting of pregnancy. Similar contraindications are noted with agents utilized in the treatment of recurrent or progressive glioblastoma. Patients with glioblastoma, IDH wildtype, should strongly consider evaluation by a high-risk obstetrician. Furthermore, it is important to discuss options for fertility preservation in patients of reproductive age prior to initiating treatment.
Anesthesia
Precautions with anesthesia are the same as for any intracranial surgery.
Media
References
- 01
- Alcantara Llaguno S, Sun D, Pedraza AM, et al. Cell-of-origin susceptibility to glioblastoma formation declines with neural lineage restriction. Nat Neurosci 2019;22(4):545-55. PMID 30778149
- 02
- Arrillaga-Romany I, Curry WT Jr, Jordan JT, et al. Performance of a hospital pathway for patients with a new single brain mass. J Oncol Pract 2019;15(3):e211-8. PMID 30681891
- 03
- Autry A, Phillips JJ, Maleschlijski S, Roy R, Molinaro AM, Chang SM, et al. Characterization of metabolic, diffusion, and perfusion properties in GBM: contrast-enhancing versus non-enhancing tumor. Transl Oncol 2017;10(6):895-903. PMID 28942218
- 04
- Balana C, Vaz MA, Sepulveda JM, et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01). Neuro Oncol 2020;22(12):1851-61. PMID 32328662
- 05
- Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016;17(11):1521-32. PMID 27686946
- 06
- Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/RTOG 0424 Trial. JAMA Oncol 2018;4(10):1405-9. PMID 29955793
- 07
- Bowers DC, Nathan PC, Constine, L et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. Lancet Oncol 2013;14(8):e321-8. PMID 23816298
- 08
- Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol 2018;136(5):805-10. PMID 30259105
- 09
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8. PMID 18772890
- 10
- Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature 2018;555(7697):469-74. PMID 29539639
- 11
- Chen H, Judkins J, Thomas C, et al. Mutant IDH1 and seizures in patients with glioma. Neurology 2017;88(19):1805-13. PMID 28404805
- 12
- Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370(21):2049. PMID 24860870
- 13
- Climans SA, Grunfeld E, Mason WP, Chan KK. Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. Neuro Oncol 2022;24(10):1738-48. PMID 35312784
- 14
- Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018;15(12):731-47. PMID 30333516
- 15
- De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 2012;30(20):2559-65. PMID 22529254
- 16
- Ellingson BM, Abrey LE, Nelson SJ, et al. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol 2018;20(9):1240-50. PMID 29660006
- 17
- Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017;35(1):96-112. PMID 28034065
- 18
- Fonkem E, Wong ET. NovoTTF-100A: a new treatment modality for recurrent glioblastoma. Expert Rev Neurother 2012;12(8):895-9. PMID 22708931
- 19
- Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4(4):296-307. PMID 15057289
- 20
- Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370(21):2048-9. PMID 24849088
- 21
- Hegi ME, Genbrugge E, Gorlia T, et al. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. Clin Cancer Res 2019;25(6):1809-16. 30514777. PMID 30514777
- 22
- Horbinski C, Ligon KL, Brastianos P, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol 2019;21(12):1498-508. PMID 31276167
- 23
- Jalali A, Amirian ES, Bainbridge MN, et al. Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. Sci Rep 2015;5:8278. PMID 25652157
- 24
- Kim M, Ladomersky E, Mozny A, et al. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv 2021;3(1):vdab125. PMID 34647022
- 25
- Kirson ED, Dbaly V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007;104(24):10152-7. PMID 17551011
- 26
- Kirson ED, Schneiderman RS, Dbaly V, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 2009;9:1. PMID 19133110
- 27
- Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013;37(5):685-98. PMID 23552385
- 28
- Liau LM, Ashkan K, Brem S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol 2023;9(1):112-21. PMID 36394838
- 29
- Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109. PMID 17618441
- 30
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131(6):803-20. PMID 27157931
- 31
- Low JT, Ostrom QT, Cioffi G, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): a summary of the CBTRUS statistical report for clinicians. Neurooncol Prac 2022;9(3):165-82. PMID 35601966
- 32
- Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13(9):916-26. PMID 22877848
- 33
- McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009;110(1):156-62. PMID 18847342
- 34
- McNulty SN, Schwtye KE, Ferguson C, et al. BRAF mutations may identify a clinically distinct subset of glioblastoma. Sci Rep 2021;11(1):19999. PMID 34625582
- 35
- Melin BS, Barnholtz-Sloan JS, Wrensch MR, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 2017;49(5):789-94. PMID 28346443
- 36
- Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol 2019;15(7):405-17. PMID 31227792
- 37
- National Comprehensive Cancer Network. Central Nervous System Cancers (Version 3.2019). Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. 2019a.
- 38
- National Comprehensive Cancer Network. Palliative Care (Version 2.2019). Available from: https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. 2019b.
- 39
- Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004;54(1):131-40; discussion 41-2. PMID 14683550
- 40
- Omuro A, Brandes AA, Carpentier AF, et al. Radiotherpay combined with nivolumab or temozolomide for newly diagnosed glioblastoma, with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol 2023;25(1):123-34. PMID 35419607
- 41
- Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2018. Neuro Oncol 2021;23(12 Suppl 2):iii1-105. PMID 34608945
- 42
- Patil N, Somasundaram E, Waite KA, et al. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. J Neurooncol 2021;155(3):363-72. PMID 34761331
- 43
- Perry JR, Laperriere N, O'Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017;376(11):1027-37. PMID 28296618
- 44
- Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115(1):3-8. PMID 21417701
- 45
- Shete S, Lau CC, Houlston RS, et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer Res 2011;71(24):7568-75. PMID 22037877
- 46
- Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW. Patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27(2):525-51. PMID 17374867
- 47
- Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011;153(6):1211-8. PMID 21479583
- 48
- Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66. PMID 19269895
- 49
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005a;352(10):987-96. PMID 15758009
- 50
- Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 2015;314(23):2535-43. PMID 26670971
- 51
- Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017;318(23):2306-16. PMID 29260225
- 52
- Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005b;5(3):198-206. PMID 15865885
- 53
- Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48(14):2192-202. PMID 22608262
- 54
- Tesileanu CM, Dirven L, Wijnenga MM, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 2020;22(4):515-23. PMID 31637414
- 55
- Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 2016;18(12):1656-63. PMID 27576872
- 56
- Weller J, Schafer N, Schaub C, et al. Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the Ce TeG/NOA-09 trial. J Neurooncol 2023;161(1):147-53. PMID 36609807
- 57
- Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 2022;23(1):53-64. PMID 34838156
- 58
- Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-15. PMID 22578793
- 59
- Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing--the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014;10(7):372-85. PMID 24912512
- 60
- Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV. Management of glioblastoma in elderly patients. J Neurol Sci 2017;380:250-5. PMID 28870580
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Ditte Primdahl MD
Dr. Primdahl of Lou and Jean Malnati Brain Tumor Institute at Northwestern Medicine has no relevant financial relationships to disclose.
See Profile
Editor
-
Rimas V Lukas MD
Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile
Former Authors
- Jennie W Taylor MD MPH
Patient Profile
- Age range of presentation
-
- 19 to 65+ years
- Sex preponderance
-
- Male > female
- Heredity
-
- Heredity may be a factor
- Population groups selectively affected
-
- None selectively affected
- Occupation groups selectively affected
-
- None selectively affected
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuro-Oncology
Tumors of the skull base
Dec. 05, 2024
-
Neuro-Oncology
Ganglioglioma
Oct. 15, 2024
-
Neuro-Oncology
Paraneoplastic syndromes
Oct. 15, 2024
-
Neuro-Oncology
Overview of neuropathology updates for infiltrating gliomas
Oct. 11, 2024
-
Neuro-Oncology
NTRK-fused tumors of the central nervous system
Oct. 07, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
Neuro-Oncology
Brain metastases
Oct. 03, 2024